🇺🇸 FDA
Pipeline program

Antithymocyte globulin (ATG)

RDCRN 5406

Phase 2 small_molecule active

Quick answer

Antithymocyte globulin (ATG) for Myelodysplastic Syndrome is a Phase 2 program (small_molecule) at Ultragenyx Pharmaceutical with 1 ClinicalTrials.gov record(s).

Program details

Company
Ultragenyx Pharmaceutical
Indication
Myelodysplastic Syndrome
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials